Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab Full Text
Annals of Oncology, 05/25/2012
Clinical Article
Rayson D et al. – Pegylated liposomal doxorubicin (PLD)+cyclophosphamide (C)+trastuzumab (H)–T + H is feasible and results in lower early cardiotoxicity rates compared with A + C-T + H.



